Signaling Pathway News and Research

RSS

CD200 stifles anti-tumor immunity

The prognosis for individuals with metastatic melanoma (MM) is not good. Therapeutic strategies to enhance the immune response have some clinical benefit; however, most patients eventually succumb to progressive disease, in part because their immune cells known as dendritic cells (DCs) fail to sustain an effective antitumor T cell immune response.

16 Nov 2007

Freeze-dried grape powder blocks genes linked to colon cancer

Low doses of freeze-dried grape powder inhibit genes linked to the development of sporadic colorectal cancer, University of California, Irvine cancer researchers found.

15 Nov 2007

Herb rosemary fights free radical damage in the brain

Rosemary not only tastes good in culinary dishes such as Rosemary chicken and lamb, but scientists have now found it is also good for your brain.

31 Oct 2007

Preventing lung scarring may extend lives of lung cancer patients

Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients – pulmonary fibrosis (scarring of the lungs), thereby extending patients' lives and improving their quality of life, according to a study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

29 Oct 2007

Discovery of a key cell-signaling pathway

University of Alabama at Birmingham (UAB) researchers have discovered a key cell-signaling pathway that regulates cell progression and switches on front-to-back body patterning in tadpoles.

28 Oct 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Positive results for novel anti-cancer drug ECO-4601

Researchers report positive results from a Phase I/II clinical trial of a novel anti-cancer drug which offers two modes of action.

24 Oct 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Insulin signaling and amphetamines

Abuse of psychostimulants such as amphetamine remains a serious public health concern.

17 Oct 2007

New insight into Herceptin resistance in breast cancer

A new study provides important insight into the mechanisms involved in resistance to treatment of breast cancer patients with trastuzumab (Herceptin). The research, published by Cell Press in the October issue of the journal Cancer Cell , identifies markers that may help to identify patients who are unlikely to respond to trastuzumab treatment and provides a potential strategy for treating these patients.

16 Oct 2007

Discovery of protein that plays a key role in the recycling of iron from blood

Scientists working in the only lab at MIT doing hematology research have uncovered a protein that plays a key role in the recycling of iron from blood. Their work, described in the October 11 Journal of Clinical Investigation, could lead to new therapies for certain inherited blood disorders such as beta-thalassemia, a condition that causes chronic anemia.

12 Oct 2007

New molecular evidence of the role of the hormone prolactin in breast cancer

They have found that prolactin, a pituitary hormone that normally stimulates breast development and milk production, initiates a new “signaling pathway” that may regulate the growth and survival of breast cancer cells.

29 Sep 2007

Enzyme's second messenger contributes to cell overgrowth

Scientists at the University of California, San Diego (UCSD) School of Medicine have uncovered a novel pathway by which hormones elevated in inflammation, cancer and cell injury act on cells to stimulate their growth.

27 Sep 2007

Study suggests brain tumors need treatment with multiple 'targeted' drugs

Researchers at Dana-Farber Cancer Institute have shown that several, rather than just one, cell-growth switches are simultaneously overactive in many brain tumors and other solid tumors, explaining why treatment with just a single "targeted" switch-blocking drug often yields disappointing results.

13 Sep 2007

New insight into breast cancer development in high-risk women

Physicians who treat women with the breast cancer susceptibility gene BRCA1 often remove their patients' ovaries to eliminate the source of estrogen they believe fuels cancer growth.

12 Sep 2007

New anti-cancer drug made from corn lillies kills brain tumor stem cells

A drug that shuts down a critical cell-signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows.

30 Aug 2007

Reactivating a critical gene lost in kidney cancer reduces tumor growth

Researchers at Mayo Clinic Jacksonville, have found that a key gene is often silenced in clear cell renal cell carcinoma, the most common type of kidney cancer, and when they restored that gene in human kidney cancer cells in culture and animal experiments, tumors stopped growing and many disappeared.

17 Aug 2007